Buscar
01/05/2024
Anticholinergic burden and revisit risk in frail patients with pharmacological sleepiness
Ruiz-Ramos, J, López-Vinardell, L, Higa-Sansone, L, Torrecilla-Vall-LLossera, B, Puig-Campmany, M, Mangues-Bafalluy, MA, Juanes-Borrego, A. Anticholinergic burden and revisit risk in frail patients with pharmacological sleepiness. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2024; 31(3)DOI:10.1136/ejhpharm-2022-003424. PMID:36100370. IF:1.500(Q4/8D).
19/03/2023
Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
Calleja M.A., Albanell J., Aranda E., García-Foncillas J., Feliu A., Rivera F., Oyagüez I., Salinas-Ortega L., Alvarez, JS. Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2023; 30(1)DOI:10.1136/ejhpharm-2021-002955. PMID:34810173. IF:1.600(Q3/8D).
01/03/2023
An antidote network in Spain, a tool to improve antidote availability in hospitals
Aguilar-Salmeron, R, Gispert-Ametller, MA, de Gamarra-Martinez, EF, Martinez-Sanchez, L, Garcia-Pelaez, M, Pi-Sala, N, Salgado-Garcia, E, Nogue-Xarau, S. An antidote network in Spain, a tool to improve antidote availability in hospitals. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2023; 30(2)DOI:10.1136/ejhpharm-2022-003328. PMID:35501035. IF:1.600(Q3/8D).
01/01/2023
Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis
Domingo C., Fernandez M., Garin N., Milara J., Moran I., Muerza I., Pacheco A., Teruel C., Bentley R., Subiran R., Gil A.. Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis. Applied Health Economics and Health Policy. 2023; 21(1)DOI:10.1007/s40258-022-00770-9. PMID:36319945. IF:3.100(Q2/3D).